Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Slides:

Advertisements

Similar presentations

Computer Solutions to Identify and Manage Women at High Risk

Advertisements

What Do We Do? Cancer Genetics Service for Wales.

Which of the following increases a women’s risk for Breast Cancer? A.Starting her menses at age 14 or older B.Breastfeeding C.Extremely dense breast tissue.

†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.

BREAST CANCER SCREENING Anoop Agrawal, M.D.. NEW USPSTF BREAST SCREENING GUIDELINES Published by US Preventative Screening Task Force in November 2009.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer Screening Guidelines: Do They All Say the Same Thing?

Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Breast Density A patient guide.

Hereditary Factors in Breast Cancer

The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.

Hereditary breast and ovarian cancer Who should be screened and How? Symposium on Cancer Waterloo Inn October 31, 2007 Mala Bahl, MD, MSc.

Breast Cancer Risk and Risk Assessment Models

Genetic Susceptibility Risk Models in Clinical Decision Making Susan M. Domchek, MD Abramson Cancer Center University of Pennsylvania.

Breast Cancer 2010 David B. Pearlstone, MD MBA FACS Co-Director, Breast Division John Theurer Cancer Center Chief, Division of Breast Surgery Hackensack.

Using the EHR for the identification of patients at high risk for hereditary breast and ovarian cancer. Brian Drohan University of Massachusetts 5/30/08.

Cancer Genetics for Primary Care Sara Levene Registered Genetic Counsellor.

Every Woman, Every Time: Disparities in Breast Cancer Tony L. Weaver, D.O. ALOMA 2015.

Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.

Ductal Carcinoma in situ

Dr. Ruth Westra Applied Anatomy September 17, 2007

SUMAYYA EBRAHIM GYNAECOLOGIST PARKLANE CLINIC JOHANNESBURG

Breast cancer screening Mammography is the most widely used screening modality, with solid evidence of benefit for women aged 40 to 74 years Clinical breast.

Jo Anne Zujewski, MD Center for Global Health National Cancer Institute, U.S.A. Dar es Salaam September 11, 2014 Breast Cancer Risk Factors and Prevention.

Mastectomy 16gene.html (article) 16gene.html

Menopause: The Journal of The North American Menopause Society

Cancer Risk Assessment Judith A Westman MD Clinical Director Division of Human Genetics.

AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.

Outcomes of screening mammography among women aged 40 to 43 Institute for Clinical Evaluative Sciences Toronto, Canada (2006)

Atoosa Adibi MD. Department of Radiology Isfahan University Of Medical Sciences.

Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.

Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.

Clinical Applications of Risk Prediction Models Laura Esserman, M.D., M.B.A. Professor of Surgery and Radiology Director, UCSF Carol Franc Buck Breast.

Assessing Risks for families with inherited cancers: an introduction to a new system Kevin Hughes, MD.

Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.

BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Associate Professor of Surgery Harvard.

Failure to appropriately screen women according to international guidelines– what are the consequences? Alison Johnston*, M Sugrue, S Curran Department.

Kevin S. Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Breast Cancer Screening. Introduction Breast cancer is a fatal disease at advanced stages; however, it can be controlled through prevention and early.

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

Breast Cancer Surveillance Consortium (BCSC): A Research Infrastructure sponsored by the National Cancer Institute Breast Cancer Risk Models William Barlow,

Breast Density: Black, White and Shades of Gray Jen Rusiecki, MD VA Pittsburgh Health System Women’s Health Fellow AMWA Hot Topic 2016.

Elizabeth Murray Clinical and Radiation Oncology.

Breast Cancer Screening and Diagnosis

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.

The Elliott Breast Center * Baton Rouge, LA *

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Harvard Medical School Date 06/01/2007.

Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.

Breast Cancer Risk Assessment & Prevention Strategies Generosa Grana, MD Professor, Cooper Medical School of Rowan University Director, MD Anderson Cancer.

Refer to Beds & Herts Breast Cancer Family History Screening service

Beaumont Hospital Breast Service

Mammograms and Breast Exams: When to start /stop mammograms

Breast Cancer Screening/Imaging

Clinical Pearls and Tools for Optimizing Breast Cancer Risk Assessment

Demystifying Cancer Genetics

Breast Screening and Risk Assessment

Breast Health Katherine B. Lee, MD, FACP April 26, 2018.

Who in the room would offer BRCA1/2 testing to this patient Who in the room would offer BRCA1/2 testing to this patient? How might the medical management.

Breast Imaging Ravi Adhikary, MD.

Refer to Beds & Herts Breast Cancer Family History Screening service

Deborah O. Himes, PhD, ANP-BC, Aubri E

BRCA1/2 Genetic Testing: Some Psychological Implications

The decision tree with the two alternatives.

Digital 2D versus Tomosynthesis Screening Mammography among Women Aged 65 and Older in the United States Screening mammography performance metrics are.

Diagnosis of breast cancer in women age 40 and younger: Delays in diagnosis result from underuse of genetic testing and breast imaging 95% of patients.

Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes Mammography screening.

Presentation transcript:

Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital Breast Center Identification and Management of Women at High Risk of Breast Cancer

Saslow D et. al. CA Cancer J Clin 2007; 57: 75

ACS MRI Guidelines Saslow D et. al. CA Cancer J Clin 2007; 57: 75

10,000 4/1/2006 to 9/17/2007 7,821 NULL or No Never HORMONES 6,981 W/ Gail Score 6,028 W/ BRCAPRO Lifetime 5,894 W/ BRCAPRO Mutation and Tyrer-Cuzick LCIS/AH status not available

ACS MRI Guidelines Exclude Gail Model …less useful than BRCAPro, Claus, and Tyrer-Cuzick …not adequate for evaluating family history Therefore we do not recommend its use for evaluating patients for breast MRI screening Online Supplemental Material

ACS Guidelines Saslow D et. al. CA Cancer J Clin 2007; 57: 75 BRCAPRO Tyrer-Cuzick Claus Gail

ACS Guidelines Claus Breast FH BRCAPRO Breast and ovarian FH Tyrer-Cuzick Breast and ovarian FH Pathologic factors Hormonal factors

Tyrer-Cuzick= 330 (5.6%) 276 BRCAPRO = 25 (0.4%) Claus = 54 (0.9%) Lifetime Breast Cancer Risk 20% or greater by Model

20 to 25% LT Risk of…What? Invasive cancer –BRCAPRO Invasive plus DCIS –Claus –Tyrer-Cuzick

Tyrer-Cuzick= 330 (5.6%) 263 Claus = 54 (0.9%) Lifetime Breast Cancer Risk 20% or greater by Model Adjusted BRCAPRO 61 (1%)

ACS MRI Guidelines Saslow D et. al. CA Cancer J Clin 2007; 57: 75 LCIS/AH

20% or greater lifetime risk –Any LCIS age 69 and below –Any AH age 56 and below Tyrer Cuzick for AH & LCIS Even more with even trivial risk factors

IDing patients for MRI is not enough Need complete risk assessment Genetic testing as appropriate Manage Breast and Ovarian Risk! Consider Genetic Testing if Risk Mutation is 10% or greater

Better Strategy Identify mutation carriers (genetic testing) –MRI for those with mutation (selective MRI) –Offer ALL risk reducing strategies Oophorectomy Prophylactic mastectomy MRI Mammography

Avon Comprehensive Breast Center Database 18,190 screening mammogram patients 40 or older –(May 2003 – July 2005) –BRCAPRO run on all

Avon Comprehensive Breast Center Database Lifetime risk ≥20% 78 (0.4%) 18,190 screening mammogram patients 40 or older –(May 2003 – July 2005) –BRCAPRO run on all

Avon Comprehensive Breast Center Database Lifetime risk ≥20% 78 (0.4%) Predicted Mutation Carriers 27 BRCAPRO 18,190 screening mammogram patients 40 or older –(May 2003 – July 2005) –BRCAPRO run on all

Avon Comprehensive Breast Center Database 374 (2.1%) Mutation Risk ≥10% Lifetime Risk <20% and 18,190 screening mammogram patients 40 or older –(May 2003 – July 2005) –BRCAPRO run on all

Avon Comprehensive Breast Center Database 374 (2.1%) Predicted Mutation Carriers 62 BRCAPRO Mutation Risk ≥10% Lifetime Risk <20% and 18,190 screening mammogram patients 40 or older –(May 2003 – July 2005) –BRCAPRO run on all

MGH Screening Data: All Comers Risk of Mutation Risk of Breast Cancer n Mean Probability of Mutation Projected # Mutation Carriers ≥10%≥20% ≥10%<20%

What to do ≥10% risk of mutation –Genetic testing Positive-Manage with all modalities Negative-Your call –Based on FH

Options for high risk

Prophylactic Oophorectomy Screening Chemoprevention Options for high risk

Conclusions ≥10% risk of mutation –Genetic testing Positive-Manage with all modalities Negative-Your call –Depend on FH ≥20% LT Risk –Lots by TC –Almost all LCIS and AH by TC –Do they all need MRI?